Skip to content
clinicaltrialshub.com
Clinical Trials Hub

Clinical trials, drug development and research news

Drug Approvals

Rare kidney disease that leaks protein gets first approved drug

The FDA approved Gazyva for primary membranous nephropathy after the MAJESTY trial, where 37% of adults reached complete remission at two years, against 6% on tacrolimus.

The Mayo and Gonda buildings of Mayo Clinic in Rochester, Minnesota, home of MAJESTY lead investigator Fernando Fervenza
Photo: Knowledge Seeker, via Wikimedia Commons · CC BY-SA 3.0
Contents
  1. What is primary membranous nephropathy?
  2. What did the MAJESTY trial test?
  3. How well did Gazyva work?
  4. What does 37% against 6% mean in practice?
  5. Did it protect kidney function?
  6. What were the side effects?
  7. What about rituximab?
  8. How did the approval come about?
  9. Who might be offered Gazyva?
  10. What can patients do now?

The US Food and Drug Administration approved Gazyva (obinutuzumab) on 13 November 2026 for adults with primary membranous nephropathy who are at risk of their disease getting worse. The FDA says it is the first drug approved specifically for this rare kidney disease. Until now, doctors have treated it with medicines borrowed from other conditions and used off-label.

The decision rests on MAJESTY, a phase 3 trial of 142 adults. After two years, 37% of people given Gazyva had their urine protein back to near-normal levels with stable kidney function, compared with 6% of those given tacrolimus, a standard immune-suppressing drug. Those figures come from the full results in the New England Journal of Medicine. The FDA's own summary rounds the Gazyva figure to 36%.

Gazyva is made by Genentech, part of the Roche Group, which also paid for the trial. It is already approved for some blood cancers, for active lupus nephritis and, since September 2026, for childhood-onset idiopathic nephrotic syndrome.

What is primary membranous nephropathy?

It is an autoimmune disease of the kidneys. The immune system attacks the glomeruli, the tiny filters that clean waste out of the blood. Once those filters are damaged, they leak large amounts of protein into the urine.

That protein loss drives most of the symptoms. The FDA lists high cholesterol, high blood pressure, severe swelling, fatigue and kidney failure among the possible effects. Many people first notice puffy ankles or legs, or frothy urine, and are diagnosed after a kidney biopsy.

"Primary" means there is no outside trigger such as an infection, a cancer or a medicine. In most cases the attack is aimed at a protein on the kidney filter called the phospholipase A2 receptor (PLA2R), and a blood test for antibodies against it is used to track the disease. Some people recover on their own. Others do not, and Genentech says that up to 30% of people with the condition develop kidney failure within 10 years, which means dialysis or a transplant.

What did the MAJESTY trial test?

MAJESTY compared two quite different ways of calming the immune attack. Gazyva is an antibody drip that wipes out B cells, the white blood cells that make the harmful antibodies. Tacrolimus, the comparison drug, is a capsule that suppresses the immune system more broadly.

The trial enrolled adults whose biopsy confirmed the diagnosis and who were still losing a lot of protein despite at least three months of standard supportive care, such as blood pressure tablets. The bar was a urine protein-to-creatinine ratio of at least 5 g/g, or at least 4 g/g after six months of supportive care. These were people with heavy, ongoing protein loss. Their kidney function also had to be reasonably preserved, with an eGFR of at least 40. People with diabetes were excluded, according to the ClinicalTrials.gov record.

Participants were randomly split into two equal groups. According to a report from the European Renal Association congress, the Gazyva group received 1,000 mg by drip on day 1 and in weeks 2, 24 and 26, so four infusions in total. The tacrolimus group took capsules daily, adjusted to a target blood level for a year and then tapered off. The study ran at about 50 sites in 11 countries, including the United States, China, Brazil and several European countries.

Both patients and doctors knew which treatment each person had. An open-label design is common when one drug is a drip and the other a pill, but it does mean expectations could colour some judgements. Lab tests of urine protein are less open to that bias than symptom scores. Our guide to open-label and blinded trials explains the trade-offs.

How well did Gazyva work?

The main measure was complete remission at week 104. To count, a person needed a urine protein-to-creatinine ratio of 0.3 g/g or lower, stable kidney function, and no rescue treatment or early exit from the study along the way.

Result at two years Gazyva Tacrolimus
Complete remission (main goal) 26 of 71 people (37%) 4 of 70 people (6%)
Complete or partial remission 51% 13%
Relapse after a remission 12% 58%

The gap in complete remission was 31 percentage points (95% confidence interval 18 to 44; P<0.001). Gazyva also came out ahead on two key secondary goals in the paper's pre-set testing order: complete or partial remission at week 104, and complete remission at week 76. The overall remission and relapse figures in the table are from the congress report.

Relapse is where the two drugs looked most different. Tacrolimus is known for working while people take it, with protein often creeping back after it stops. In MAJESTY, more than half of the tacrolimus patients who went into remission had relapsed by week 104. On Gazyva the figure was 12%.

What does 37% against 6% mean in practice?

Picture 100 people with this disease who need treatment. On the MAJESTY numbers, about 37 would reach full remission at two years on Gazyva, against about 6 on tacrolimus. That works out at roughly 31 extra people in full remission for every 100 treated, or about one extra full remission for every three people who get Gazyva.

Put the other way round, around 63 in every 100 on Gazyva did not reach the strict complete remission mark by week 104. Some of them reached partial remission, which still means much less protein in the urine. Our explainer on how to read clinical trial results covers why the absolute gap is often more useful than the headline percentages.

Did it protect kidney function?

Not yet, at least on the evidence so far. One of the pre-planned secondary goals was a sustained drop of 30% or more in eGFR, a measure of how well the kidneys filter. The NEJM abstract reports that this analysis did not show a significant difference between the groups.

That result also stopped the statistical chain. Because the trial tested its goals in a fixed order, the later measures, including how long remission lasted and a fatigue score, were not formally tested.

There is a reason the FDA approved the drug to "induce remission of proteinuria" and said nothing about kidney failure. Two years is short for a disease that can take a decade to damage the kidneys. Genentech describes complete remission as the main goal of treatment, one that can help prevent kidney failure, but MAJESTY was not long enough to show that directly. The study is still running, with a completion date in late 2027 listed on ClinicalTrials.gov.

What were the side effects?

Serious side effects were similar between the two drugs. In the NEJM paper, grade 3 or worse adverse events affected 22% of people on Gazyva and 19% on tacrolimus. Serious adverse events occurred in 17% and 14%.

Infections are the obvious worry with a drug that removes B cells. The rates were close: 61 infections per 100 patient-years on Gazyva and 57 on tacrolimus, with serious infections at 3 and 4 per 100 patient-years. One person in each group died, in both cases while on escape (rescue) therapy.

The side effects specific to Gazyva were infusion reactions, respiratory tract infections and a drop in neutrophils, a type of white blood cell. Infusion reactions affected 38% of the Gazyva group in the congress report, and the trial record lists a steroid, paracetamol and an antihistamine given alongside the drip to reduce them.

Gazyva's US label also carries a boxed warning, the FDA's strongest, for two rare but serious risks. The first is reactivation of hepatitis B in people who carry the virus, so people are tested before starting. The second is progressive multifocal leukoencephalopathy (PML), a rare brain infection that can affect people with weakened immune systems. Our article on a new hepatitis B treatment has more on that virus.

What about rituximab?

This is the question many kidney doctors will ask. Rituximab is an older antibody that also targets CD20 on B cells, and it is already widely used off-label for membranous nephropathy. The KDIGO 2021 guideline on glomerular diseases lists rituximab, cyclophosphamide with steroids, and calcineurin inhibitors such as tacrolimus among the treatment options, chosen by how likely the disease is to progress.

MAJESTY did not compare Gazyva with rituximab, so the trial cannot say whether Gazyva is better than the drug many patients already receive. Gazyva is a different type of anti-CD20 antibody. Genentech says it was engineered for deeper B-cell depletion, including in tissues, and the NEJM authors describe more profound and longer-lasting depletion with this type of antibody. Whether that gives a real advantage over rituximab in this disease would need a head-to-head trial.

What the approval does change is the paperwork. A licensed indication gives doctors dosing, safety and efficacy data reviewed by the regulator, and in some health systems that can make a drug easier to get funded than an off-label one.

How did the approval come about?

The timeline was fast by FDA standards.

  1. Genentech announced on 15 February 2026 that MAJESTY had met its main goal.
  2. The FDA granted Breakthrough Therapy Designation in April 2026.
  3. Full results were presented as a late-breaking talk at the European Renal Association congress in June 2026 and published in NEJM.
  4. On 14 July 2026, Genentech said the FDA had accepted its application for priority review.
  5. The FDA approved Gazyva for this use on 13 November 2026.

The application also had Orphan Drug designation, which applies to conditions affecting fewer than 200,000 people in the US. Our guide to how new medicines get approved explains what priority review and breakthrough status mean.

Outside the US, there is no decision yet. Genentech said in February that the data would go to the European Medicines Agency as well as the FDA. We found no announced EU or UK decision in the sources we reviewed.

Who might be offered Gazyva?

The US label covers adults with primary membranous nephropathy "at risk of disease progression". That broadly matches the MAJESTY population: people with heavy, persistent protein loss despite supportive care. The trial excluded people with diabetes, secondary causes of the disease, severe kidney impairment and recent use of other anti-CD20 drugs, so there is less evidence for those groups.

At the time of writing, the FDA announcement did not give the dosing schedule for this use, and we did not find a published price for a course. The dosing used in MAJESTY is described above. Your kidney team will be the ones to say whether a drug like this fits your case.

Kidney disease is a growing area on this site. We recently covered two-year results for atacicept in IgA nephropathy, another autoimmune kidney condition where trials have focused on cutting protein in the urine.

What can patients do now?

If you have membranous nephropathy and your urine protein has stayed high, it is reasonable to ask your nephrologist about your risk of progression and whether B-cell treatment is an option. Bring your latest urine protein and anti-PLA2R antibody results to the appointment.

Questions worth asking:

  • How likely is my disease to get worse without stronger treatment?
  • Would rituximab, Gazyva or another option suit me, and why?
  • How will we track whether I am in remission?
  • Have I been tested for hepatitis B?

If you are outside the US, Gazyva is not licensed for this use yet, though trials are another route. Our guide on how to find and join a clinical trial explains how to search by condition.

This article is for information only and is not medical advice. Talk to your kidney specialist before starting, stopping or changing any treatment.

Frequently asked questions

What is Gazyva approved for in membranous nephropathy?

On 13 November 2026 the FDA approved Gazyva (obinutuzumab) for adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria (protein in the urine). The FDA says it is the first drug approved specifically for this disease in adults. The approval is for the United States only.

How effective was Gazyva in the MAJESTY trial?

After two years, 26 of 71 people on Gazyva (37%) reached complete remission, meaning urine protein at or below 0.3 g/g with stable kidney function, compared with 4 of 70 on tacrolimus (6%). The FDA rounds these to 36% and 6%. Gazyva also beat tacrolimus on complete or partial remission at two years.

Is Gazyva better than rituximab for membranous nephropathy?

Nobody knows yet. MAJESTY compared Gazyva with tacrolimus, not with rituximab, which many kidney doctors already use off-label. Both drugs target CD20 on B cells, and Genentech says Gazyva was engineered for deeper B-cell depletion. Only a head-to-head trial could show whether that makes a difference to patients.

What are the main side effects of Gazyva?

In MAJESTY, infusion reactions, respiratory tract infections and low neutrophil counts were the drug-related side effects. Serious side effects affected 17% on Gazyva and 14% on tacrolimus. The label has a boxed warning for hepatitis B reactivation and progressive multifocal leukoencephalopathy, a rare brain infection, so people are tested for hepatitis B first.

Is Gazyva approved for membranous nephropathy in the UK or EU?

Not as of mid-November 2026. Genentech said in February 2026 that the MAJESTY data would be shared with the European Medicines Agency as well as the FDA, but no EU or UK decision had been announced in the sources we reviewed. People outside the US may be able to access similar drugs off-label or through clinical trials.

Sources

  1. FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy. US Food and Drug Administration, 2026-11-13
  2. Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy (Fervenza FC, et al.). New England Journal of Medicine, 2026-06-05
  3. Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy, abstract, PMID 42246654. PubMed, 2026-09-10
  4. A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy (MAJESTY), NCT04629248. ClinicalTrials.gov, 2026-11-15
  5. Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy. Genentech, 2026-02-15
  6. FDA Grants Priority Review to Genentech's Gazyva for Adults With Primary Membranous Nephropathy. Genentech, 2026-07-14
  7. Obinutuzumab Superior to Tacrolimus for Adults With Primary Membranous Nephropathy (ERA 2026 report). Renal and Urology News, 2026-06-08
  8. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. KDIGO, 2021-10-01
  9. Notable Approvals, Drugs. US Food and Drug Administration, 2026-11-13

Medical disclaimer: For information only, not medical advice. Speak to a qualified healthcare professional about your care.

The Briefing

Trial results that matter, every Friday.

One email. The week's readouts, approvals and research, explained without hype.

Related reading